Ro5

Ro5 is a startup in the biotechnology, healthcare, and pharmaceutical industries, headquartered in the United Kingdom. Established in 2018, the company focuses on bioactivity, de novo drug discovery, ADMET, and knowledge graph.

Ro5's slogan, "Bioactivity. De Novo Drug Discovery. ADMET. Knowledge Graph.", encapsulates the essence of its offerings. The startup aims to democratize AI in drug discovery by providing an accessible AI software platform. This platform empowers drug discovery researchers to concentrate on their expertise, while Ro5 takes care of the digital transformation through its expertise, infrastructure, software, models, and data.

The company's services and software cater to pharmaceutical companies and contract research organizations (CROs), covering the entire drug discovery and development process. With 5 years of experience, Ro5 has amassed a strong portfolio, including 3 scientific papers and 13 awarded patents.

As of the most recent update, Ro5 secured a Seed Round investment on 01 February 2020. Despite no specific information on the investors, the startup is well-positioned with its expertise and offerings. Overall, Ro5 presents a compelling proposition for organizations seeking to embrace digital transformation for drug discovery.